Okay, my holiday break was a little long, but the blogging business can only compensate for the lousy pay with generous holiday allotment. And so far 2010 is looking good, rheumatologically speaking. Not three weeks in and the FDA has given the nod to tocilizumab (Actemra), the latest biological in the anti-RA arsenal. We now enter the next decade with five ant-TNFs, abatacept, rituximab and tocilizumab. We'll have to add more seats in the waiting room for all the drug reps, but the more the merrier I say. Surely one of them will have to break rank and bring down the prices.